Barely Significant
← all excerpts

Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2.

Neurology · 2020 · PMC7274916 · PMID 32209650

Europe PMCDOI
1
hedged sentence
0.0010
closest p · 0.0× alpha
0.0010
boldest claim

The sentences

nominally significantp = 0.001actually significant
The estimated mean difference from placebo for the 100 mg treatment group (a prespecified endpoint) was −1.7 and was nominally significant ( p = 0.001), although this comparison was not formally included within the prespecified testing algorithm.

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.